Lymph node metastasis (LNM) considerably impacts illness staging, scientific administration, and prognostic consequence [1], highlighting the significance of systematic lymph node resection as a standardized surgical process for most cancers [2]. Furthermore, residual tumor tissue and metastatic LNs are the main causes of most cancers relapse and metastasis after surgical procedure[3], [4]. Nevertheless, postoperative pathology confirms LNM in fewer than 20% of most cancers sufferers, suggesting that just about 80% endure pointless lymphadenectomy [5]. Moreover, LNs have been acknowledged as the important thing organ in immune response to most cancers, notably within the context of immunotherapy[6], [7], additional supporting the potential advantages of non-surgical therapy methods for LNs with tumor metastasis. Sentinel lymph node biopsy (SLNB) has been used as a substitute for lymphadenectomy in scientific apply for a lot of strong tumors [8], whereas its software is proscribed by the poor concentrating on efficacy of the imaging brokers (as an example, radioisotopes) and their related toxicity [9]. In the meantime, intraoperative frozen part pathology of LN is time-consuming and vulnerable to diagnostic errors. Along with the shortage of fast and correct analysis, the therapy of LN metastasis is additional restricted by the inefficiency of drug supply. Chemotherapy can suppress lymph node metastasis of tumors. Nevertheless, systematically administered chemotherapeutics are likely to accumulate in main organs and have restricted entry to the lymphatic system, considerably compromising their effectiveness towards lymphatic metastases. Due to this fact, it stays a major problem to specific eradicate the residual tumors and selectively suppress the metastatic tumors in LNs for bettering the scientific prognostic consequence following most cancers surgical procedure.
Leveraging the physiological construction of the lymphatic system, nanoparticles sized 10–100 nm are optimum for passive lymphatic uptake and LN concentrating on [10], [11]. Numerous lymphatic-targeted drug supply nanocarriers have been developed to ship therapeutics into LNs, together with polymer-based micelle [12], cell membrane-derived nanoparticle [13], liposomes [14], mesoporous silica nanoparticles (MSN) [15], and the broadly investigated lipid nanoparticles (LNPs) [16]. However, the low concentrating on selectivity of nanocarriers between metastasis and regular LNs makes it tough to tell apart metastatic lesions from wholesome LN tissues. Furthermore, the heterogeneity expression of receptors throughout tumors restricts the broad software of the supply programs that depend on ligand-based energetic concentrating on nanoparticles [17]. These limitations tremendously hinder their scientific software within the therapy of LN metastasis. One other main concern with chemotherapy is the intense toxicity and uncomfortable side effects attributable to the undesired launch of chemotherapeutic brokers in wholesome tissues. The bodily encapsulation design of most cancers nanotherapeutics in scientific use, resembling Abraxane® and Doxil®, at all times results in untimely launch of energetic medicine throughout bloodstream circulation, contributing to excessive toxicity and unsatisfactory anti-tumor outcomes [18], [19], [20]. Stimuli-responsive and pro-drug designs in sensible nanomedicines allow tissue-specific and gate-controlled activation and launch of drugs, thereby minimizing uncomfortable side effects and enabling exact most cancers remedy [21], [22]. In recent times, we now have developed an ultra-pH-sensitive (UPS) nanoplatform that leverages the acidic properties of the tumor microenvironment for exact most cancers imaging [23], [24] and drug supply [25], [26]. The UPS nanotechnology relies on ionizable amphiphilic block copolymers that exhibit an ultrasharp pH transition (∼ 0.2 pH items). This distinctive property permits the nanoparticles to stay steady beneath physiological situations but quickly disassemble (inside ∼2 ms) within the barely acidic tumor microenvironment or endocytic organelles, accompanied by as much as 100-fold sign amplification, thereby offering a strong technique for tumor-selective imaging and drug supply. Primarily based on the UPS nanotechnology, we now have constructed a pH-amplified chemiluminescence resonance vitality switch (CRET) nanosensor (PCN) for noninvasive identification of tumor metastatic standing in sentinel lymph nodes (SLNs) [27]. The self-illuminating luminol part in PCN can report the exercise of myeloperoxidase (MPO), a biomarker of inflammatory phagocytes in metastatic SLNs [28]. Upon catalysis with MPO, luminol emits luminescence, which subsequently excites the near-infrared (NIR) fluorescent probe pyropheophorbide-a (PPa) through CRET, changing the luminescence into NIR mild to point the incidence of LN metastasis [29].
Herein, we design a self-illuminating and pH-MPO-ROS cascade-activatable prodrug nanoparticle (PCAPN) to additional equip the PCN nanoprobe with therapeutic operate for selectively eliminating the residual tumors and metastatic LNs after surgical procedure (Fig. 1). The broadly used chemotherapeutic agent, paclitaxel, is conjugated to the UPS polymer spine through a reactive oxygen species (ROS)-responsive linkage, serving as the bottom drug unit. After particular activation and self-illuminating in tumor and metastatic LNs, the MPO-boosted PPa photosensitizer additional generates ROS, enabling the in situ launch of paclitaxel (PTX) for secure and efficient therapy of most cancers and metastatic LNs. This tri-gate design presents a promising and rational technique for postoperative chemotherapy.